XML 25 R14.htm IDEA: XBRL DOCUMENT
v3.21.1

Stock-based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] |
Stock-based Compensation | NOTE 8 —Stock-based Compensation As of March 31, 2021, the Company had the 2012 Equity Incentive Plan (the “2012 Equity Plan”) and 2019 Equity Incentive Plan (the “2019 Equity Plan”) and the 2019 Employee Stock Purchase Plan in place. As of March 31, 2021, the number of shares available to be issued under the 2019 Equity Plan was 6,259,229. As of March 31, 2021, the number of shares available to be issued under the 2019 Employee Stock Purchase Plan was 780,438. The 2019 Equity Plan provides for the grant of incentive and non-statutory stock options (“Options”), stock appreciation rights (“SAR”), restricted stock awards (“RSA”), and restricted stock unit awards (“RSU”) to employees, nonemployee directors, and consultants of the Company. Option awards granted under the 2019 Equity Plan generally become exercisable ratably over a two-year or four-year period following the date of grant and expire ten years from the date of grant. At the discretion of the Board of Directors, certain awards may be exercisable immediately at the date of grant but are subject to a repurchase right, under which the Company may buy back any unvested shares at their original exercise price in the event of an employee’s termination prior to full vesting. All other awards are exercisable only to the extent vested. At March 31, 2021 and December 31, 2020, there were no shares that had been early exercised that were subject to the Company’s repurchase right at that date. The exercise price or strike price for Options and SARs granted under the 2019 Equity Plan must generally be at least equal to 100% of the fair value of the Company’s common stock at the date of grant, as determined by the Board of Directors. The exercise price of incentive stock options granted under the 2019 Equity Plan to ten percent or greater stockholders must be at least equal to 110% of the fair value of the Company’s common stock at the date of grant, as determined by the Board of Directors, and are not exercisable after five years from the date of grant. The Company’s board of directors adopted, and its stockholders approved, the 2019 Employee Stock Purchase Plan and the 2019 Equity Plan in March 2019 and April 2019, respectively, each of which became effective in connection with the IPO. There are 1,041,379 shares of common stock reserved for issuance under the 2019 Employee Stock Purchase Plan as of March 31, 2021. Additionally, the number of shares of common stock reserved for issuance under the 2019 Employee Stock Purchase Plan automatically increases on January 1 of each calendar year for 10 years, starting January 1, 2020, and ending on, and including, January 1, 2029, in an amount equal to the lesser of 1% of the total number of shares of capital stock outstanding on December 31st of the prior calendar year, and (ii) 500,000 shares, unless the Board of Directors or the compensation committee of the Board of Directors determines prior to such date that there will be a lesser increase, or no increase. The increase under the 2019 Employee Stock Purchase Plan for 2021 was 500,000 shares. As of March 31, 2021, 9,222,443 shares of common stock are reserved for future issuance under the 2019 Equity Plan, plus the number of shares subject to outstanding stock options or other stock awards that were granted under the 2012 Equity Plan that are forfeited, terminated, expire or are otherwise not issued. Additionally, the number of shares of common stock reserved for issuance under the 2019 Equity Plan automatically increases on January 1 of each calendar year for 10 years, starting January 1, 2020 and ending on and including January 1, 2029, in an amount equal to 5% of the total number of shares of capital stock outstanding on December 31 of the prior calendar year, unless the Board of Directors or compensation committee determines prior to the date of increase that there will be a lesser increase, or no increase. The increase under the 2019 Equity Plan for 2021 was 3,315,543 shares. On November 15, 2020, 128,015 shares of common stock were issued under the 2019 Employee Stock Purchase Plan. Stock-based compensation expense for the three months ended March 31, 2021 and 2020 is as follows:
|  | March 31, 2021 |  |  | March 31, 2020 |
Research and development |  | $ | 50 |  |  | $ | 60 |
Sales and marketing |  | 56 |  |  | 57 |
General and administrative |  | 174 |  |  | 96 |
Cost of revenues |  | 16 |  |  | 10 |
|  | $ | 296 |  |  | $ | 223 |
Stock Options: Stock option activity for the three months ended March 31, 2021 is as follows:
|  |  |  |  |  |  |  |  |  | Weighted average |  |  |  |  |
|  |  |  |  |  | Weighted average |  |  |  | remaining |  |  |  | Aggregate |
|  |  |  |  |  | exercise price |  |  |  | contractual life |  |  |  | Intrinsic |
|  | Options |  |  |  | per share |  |  |  | (in years) |  |  |  | Value |
Outstanding at January 1, 2021 |  | 1,443,940 |  |  | $ | 3.64 |  |  |  | 7.82 |  |  | $ | 24 |
Options granted |  | — |  |  | $ | — |  |  |  |  |  |  |  |  |
Options exercised |  | (7,082 | ) |  | $ | 0.75 |  |  |  |  |  |  |  |  |
Options forfeited |  | (4,180 | ) |  | $ | 9.70 |  |  |  |  |  |  |  |  |
Options expired |  | (17,792 | ) |  | $ | 2.62 |  |  |  |  |  |  |  |  |
Outstanding at March 31, 2021 |  | 1,414,886 |  |  | $ | 3.65 |  |  |  | 7.66 |  |  | $ | 37 |
Vested and expected to vest at March 31, 2021 |  | 1,414,886 |  |  | $ | 3.65 |  |  |  | 7.66 |  |  | $ | 37 |
Exercisable at March 31, 2021 |  | 710,832 |  |  | $ | 4.18 |  |  |  | 6.68 |  |  | $ | 37 |
As of March 31, 2021, there was approximately $2,983 of unamortized stock-based compensation cost related to unvested stock options, which is expected to be recognized over a weighted average period of approximately three years. Restricted Stock Units: The following table summarized the outstanding RSUs as of March 31, 2021:
|  | RSUs |
Outstanding at January 1, 2021 |  |  | 2,691,375 |
Granted |  |  | — |
Released |  |  | — |
Forfeited |  |  | — |
Outstanding at March 31, 2021 |  |  | 2,691,375 |
Exercisable March 31, 2021 |  |  | — |
As of March 31, 2021, unvested restricted stock units totaled 2,691,375 shares. There were no RSU’s issued for the three months ended March 31, 2021 and 2020.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration